candesartan cilexetil / Generic mfg. - LARVOL DELTA

Influence of Valsartan or Olmesartan on renin-angiotensin-aldosterone system and cardiac muscle (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Nihon University School of Medicine; Sekino Hospital | Unknown status ➔ Completed

Trial completion • Cardiovascular • Hypertension

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Disseminated adenovirus and rejection in a kidney transplant recipient: Walking the fine line between infection and rejection (TTS 2026) - "Primary renal pathology was anti glomerular basement membrane disease diagnosed in 2022, managed with therapeutic plasma exchange (TPE), corticosteroids and cyclophosphamide...Transplant induction regimen included tacrolimus, mycophenolate mofetil (MMF), basiliximab and corticosteroids...One month post kidney transplantation macroscopic haematuria developed and persisted despite therapy of Enterobacter cloacae and Streptococcus mitis bacteriuria with ciprofloxacin followed by ertapenem...Cidofovir was then commenced at 2.5mg/kg weekly for two weeks then fortnightly with probenecid and intravenous (IV) fluid therapy...This was treated with pulse IV methylprednisolone and MMF recommenced at 250mg twice daily. Follow up biopsy showed features of antibody mediated rejection which was managed with an increase in MMF and candesartan for a detected angiotensin receptor 1 antibody... We present a case of disseminated adenovirus infection post kidney transplantation. This case..."

Clinical • Antibody-mediated Rejection • Autoimmune Hemolytic Anemia • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Solid Organ Transplantation • Transplantation

Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus. (PubMed, J Hum Hypertens) - "Secondary analyses were also not significantly different. Overall, this study did not detect sufficient evidence that telmisartan reduces NODM risk compared with losartan, valsartan, or candesartan."

Journal • Diabetes • Metabolic Disorders • PPARG

Candesartan for Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Clin Neuropharmacol) - "Candesartan is effective as a preventive treatment for migraine. However, further studies must be conducted globally in larger, more diverse, and longer-term patient populations."

Journal • Retrospective data • CNS Disorders • Migraine • Pain

Racial differences on treatment response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT Trial investigators Background:Racial differences in treatment response to antihypertensive combination therapies remain uncertain.Purpose: To assess whether race modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial was a randomized, double-blind, multicenter study conducted in Brazil, comparing a novel triple single-pill (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) in patients with uncontrolled hypertension. Race does not seem to influence treatment response to single triple-pill combination therapies. The comparative treatment effect of the novel triple single-pill versus active control was consistent across racial groups, with no evidence of effect modification. These findings support the broad applicability of triple single-pill regimens across diverse racial populations."

Cardiovascular • Hypertension

Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT trial investigators Background: Although cardiovascular risk guides initiation of antihypertensive therapy, its influence on the response to single-pill combination regimens remains unclear.Purpose: To assess whether baseline cardiovascular risk modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial compared a novel triple single-pill combination (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) in patients with uncontrolled hypertension. Patients at low/intermediate cardiovascular risk appeared to achieve greater overall SBP reductions than those at high risk. The treatment effect of the novel triple single-pill relative to active control was consistent across cardiovascular risk strata, with no evidence of effect modification. These findings suggest that risk stratification may help..."

Cardiovascular • Hypertension

Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT Trial (ESC 2026) - "On behalf: OPTION TREAT Trial investigators Background: Further research is needed to better understand sex differences in antihypertensive response to triple single-pill combinations, particularly given the increasing use of these regimens in contemporary clinical practicePurpose: To assess whether sex modifies treatment effects on systolic blood pressure reduction at 12 weeks. The OPTION TREAT trial was a randomised, double-blind, multicenter study conducted in Brazil, comparing a novel triple single-pill combination (candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg) with an active control (valsartan 160 mg, hydrochlorothiazide 12.5 mg, and amlodipine 5 mg) for patients with uncontrolled hypertension. Women appear to achieve greater response to antihypertensive single-pill combination therapy than men. No difference was observed regarding the treatment effect of the novel triple single-pill combination compared to the active control according..."

Cardiovascular • Hypertension

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure. (PubMed, J Am Coll Cardiol) - P3 | "In patients with HF, hemoglobin concentrations associated with the lowest risk of death and HF hospitalization were approximately 14 g/dL in women and 15 g/dL in men. Hemoglobin concentrations above WHO anemia thresholds may still carry prognostic information and, in conjunction with other clinical findings, may prompt consideration of potentially reversible contributors such as iron deficiency. (Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Added], NCT00634309; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Alternative], NCT00634400; Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Preserved], NCT00634712; A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF], NCT00232180; Irbesartan in..."

Clinical data • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders

Metabolic and Inflammatory Adverse Drug Reactions Associated with Amlodipine: A Descriptive and Disproportionality Analysis of EudraVigilance Reports. (PubMed, Pharmaceuticals (Basel)) - " "Hyperglycaemia" could be considered a safety signal for amlodipine, compared to beta-blockers (e.g., bisoprolol-ROR: 2.56), ACE inhibitors (e.g., ramipril-ROR: 2.82), and sartans (e.g., candesartan-ROR: 3.85). "Metabolic syndrome" was reported for amlodipine with a lower probability than for hydrochlorothiazide (ROR: 0.35). Inflammatory signals (e.g., increased C-reactive protein) appeared less frequently for amlodipine than for certain renin-angiotensin-aldosterone system inhibitors (e.g., perindopril-ROR: 0.53)...Reports of inflammation likely reflect patient comorbidities rather than a direct drug effect. These findings demonstrate that post-marketing surveillance remains essential, even when accounting for the methodological limitations of spontaneous reporting."

Adverse drug reaction • Journal • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • CRP

Renin-Angiotensin System Inhibitor Use and Mortality in Older Hypertensive Patients With and Without Dementia: A Nationwide Registry-Based Cohort Study. (PubMed, J Clin Hypertens (Greenwich)) - "Cox regressions compared mortality risk among RASI users versus non-users, ACEI users versus ARB users, and users of enalapril, ramipril, losartan, and candesartan versus other RASI users. RASI use was associated with lower all-cause mortality among older hypertensive patients, including those with dementia. These observational findings support continued attention to evidence-based hypertension treatment in patients with dementia."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Hypertension

Reduced Codeine Analgesic Efficacy Associated with Nicardipine in a Patient with Medication-Overuse Headache: A Case Report. (PubMed, J Pain Palliat Care Pharmacother) - "Codeine is a prodrug opioid whose analgesic efficacy depends on its bioactivation into morphine via cytochrome P450 2D6...Plasma concentrations of codeine and its metabolites were measured before and after codeine intake under nicardipine treatment and three months after substitution with candesartan...This case highlights a clinically relevant interaction between nicardipine and codeine leading to reduced opioid efficacy. Beyond tolerance and medication-overuse headache, pharmacokinetic interactions should be systematically considered in patients with refractory pain."

Journal • CNS Disorders • Migraine • Pain

Non-dihydropyridine Calcium Channel Blockers in Atrial Fibrillation with Mildly Reduced Ejection Fraction: Caution is Still AdvisedReplyBrazilian Atrial Fibrillation Guidelines - 20252016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology... (PubMed, Arq Bras Cardiol) - No abstract available

Clinical guideline • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Comparative efficacy of pharmacological therapies in non-obstructive hypertrophic cardiomyopathy: a frequentist network meta-analysis. (PubMed, Eur J Clin Pharmacol) - "Different pharmacological therapies may provide benefits in specific physiological domains in patients with non-obstructive HCM; however, no single therapy demonstrated consistent improvements across all evaluated outcomes. These findings highlight the heterogeneity of treatment effects and suggest that targeting multiple pathophysiological pathways may be important. Larger randomized and head-to-head comparative studies are needed to define optimal management in this population."

Clinical • Journal • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Identification of hypertension-associated bacterial key genes as potential targets and therapeutic agents through integrated bioinformatics approach. (PubMed, Int Microbiol) - "Structure-based molecular docking identified five approved drugs, namely Azilsartan, Eplerenone, Candesartan, Conivaptan, and Telmisartan, as top-ranked compounds exhibiting strong binding affinities toward the proposed targets. Therefore, this study identifies microbial gene signatures potentially involved in HTN and proposes a microbiome-guided drug repurposing strategy targeting bacterial functional pathways. These findings provide novel insights into microbiota-host interactions in HTN and highlight promising therapeutic candidates that warrant further experimental and clinical validation."

Journal • Cardiovascular • Hypertension

Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis. (PubMed, Am J Cardiovasc Drugs) - "This study supports that ARBs with inverse agonism, especially AZL-M, have a better BP-lowering efficacy compared with ARBs without inverse agonism and ARNIs, while maintaining favorable safety profiles. Future research is encouraged to explore the effects on long-term outcomes, combination therapies, and safety in diverse populations."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension

Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry. (PubMed, J Headache Pain) - "This French real-word study confirms the effectiveness and safety of eptinezumab in difficult-to-treat patients with migraine who and have failed non-specific preventive migraine treatments and are naïve to Calcitonin Gene Related Peptide monoclonal antibodies."

Clinical • Journal • Real-world evidence • CNS Disorders • Depression • Immunology • Migraine • Mood Disorders • Pain • Psychiatry

Identification of organic micropollutants and transformation processes in an agricultural and urban river catchment applying target and non-target analysis. (PubMed, Sci Total Environ) - "Thereby, mean concentrations of candesartan and valsartanic acid as well as the carbamazepine metabolite 10,11-dihydro-10,11-dihydroxycarbamazepine exceeded health orientation values. The exact mechanisms need to be further evaluated. The present study provides valuable insights to stressors in high modified water bodies and shows that fold change analysis after non-target data processing is a valuable tool to gain insights into transformation processes in lakes and rivers which can aid in prioritizing research in the future."

Journal

Design-Assisted Chemometric UV Spectrophotometric Determination of Candesartan Cilexetil, Chlorthalidone and Amlodipine Using Principal Component Regression, Partial Least Squares and Genetic Algorithm-Partial Least Squares Models. (PubMed, Anal Sci Adv) - "In addition, the graphical layout tool for analytical chemistry evaluation (GLANCE) visualization framework provided a comprehensive graphical assessment of analytical performance and sustainability metrics. The proposed chemometric strategy offers a rapid, reliable, cost-effective and environmentally friendly alternative for routine quality control of multicomponent pharmaceutical formulations."

Journal • Acute Myelogenous Leukemia

Removal of organic micropollutants in granular activated carbon filters - review of long-term and full-scale experiences from municipal wastewater treatment. (PubMed, Water Sci Technol) - "Breakthrough of indicator compounds varied widely, but citalopram, metoprolol, benzotriazole, and methylbenzotriazole generally showed relatively late breakthrough, indicating potential for longer filter lifespan, whereas candesartan and irbesartan more often showed early breakthrough. However, the limited number of long-term full-scale studies and the large variability in pre-treatment, filter design, carbon type, and operating conditions prevent robust quantitative assessment of these relationships. The findings highlight the need for more large-scale, long-term studies using a systematic evaluation framework to support the effective implementation of GAC filtration for UWWTD compliance."

Journal • Review

Prediction of migraine treatment response with clinical and genetic data: A machine learning analysis of the HUNT study. (PubMed, Cephalalgia) - "We developed models that predicted treatment responses to amitriptyline, beta-blockers, candesartan and topiramate with modest accuracy. Incorporating genetic data did not enhance performance, although the limited sample size and the uncertain accuracy of cohort definition and treatment response assessment prevent firm conclusions."

Journal • CNS Disorders • Migraine • Pain • Preventive care

Real-world assessment of effectiveness and safety of candesartan in migraine prevention: Results of the French FHU InovPain registry. (PubMed, Rev Neurol (Paris)) - "In this real-world observational cohort, candesartan was associated with clinically meaningful reductions in migraine burden by M3, including in conservative modified ITT/LOCF analyses. Longer-term observed-case data suggested persistence of response among treatment continuers, but should not be interpreted as population-level effectiveness. These findings support candesartan as a pragmatic oral preventive option across migraine phenotypes, while highlighting the need for cautious interpretation of observational data and for prospective comparative studies."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Nose-to-brain delivery of candesartan-loaded nanoemulsion: brain biodistribution and neurobehavioral outcomes in controlled cortical impact-induced traumatic brain injury. (PubMed, Inflammopharmacology) - "The levels of pro-inflammatory cytokines were lower in the CND-MNE-treated group than in the group treated with IN CND-SUS, indicating reduced neuroinflammation. Collectively, these findings highlight the potential of CND-MNE as an effective non-invasive strategy for targeted brain delivery and neuroprotection in TBI."

Journal • CNS Disorders • Inflammation • Vascular Neurology

Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data. (PubMed, Front Pharmacol) - "Monthly procurement data for four NVBP antihypertensive drugs (Olmesartan Medoxomil, Candesartan Cilexetil, Terazosin Hydrochloride, and Indapamide) were collected from January 2019 to April 2021, covering 16 months before and 12 months after policy implementation (May 1, 2020). These findings, based on procurement records rather than patient-level data, suggest that price reductions alone may not ensure consistent procurement patterns. Strengthening supply chain resilience and aligning procurement schedules with clinical demand may support more stable drug supply in disadvantaged regions."

Journal • Cardiovascular • Hypertension